to compare the efficacy and patient acceptability of lactitol vs. lactulose in chronic recurrent portal-systemic encephalopathy ( pse ) , 25 cirrhotic patients with a history of repeated episodes of hepatic encephalopathy who required chronic administration of lactulose were included in a controlled cross-over clinical trial in which patients received , at random , lactitol ( at an initial dosage of 10 g/6 h ) or lactulose ( 15 ml/6 h , 66 % w/v , containing 10 g of lactulose ) during a 3 month period and then crossed-over to the alternative treatment for the following 3 months .
C0019151
hepatic encephalopathy
C0022957
lactulose